You just read:

Theravance Biopharma and Mylan Report Positive New Data from Multiple Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting

News provided by

Theravance Biopharma, Inc. , Mylan N.V.

Oct 11, 2018, 08:30 ET